Macrophages and the kidney

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 3, 2004, Pages 285-290

  Wilson, Heather M ^a   Walbaum, David ^a   Rees, Andrew J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Glomerulonephritis; Kidney; Macrophage; Macrophage activation; Monocyte

Indexed keywords

CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; DOWN REGULATION; HUMAN; IN VIVO STUDY; INFLAMMATION; KIDNEY DISEASE; KIDNEY INJURY; MACROPHAGE; MOLECULAR BIOLOGY; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TISSUE REPAIR;

GLOMERULONEPHRITIS; HUMANS; KIDNEY; MACROPHAGE ACTIVATION; MACROPHAGES;

EID: 2342576796     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200405000-00004     Document Type: Review

References (55)

1. Franc NC. Phagocytosis of apoptotic cells in mammals, Caenorhabditis elegans and Drosophila melanogaster: molecular mechanisms and physiological consequences. Front Biosci 2002; 7:d1298-d1313.
2. Rosenberger CM, Finlay BB. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat Rev Mol Cell Biol 2003; 4:385-396. This is an excellent review on the interference strategies used by bacterial antigens to undermine macrophage signalling.
3. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-265.
4. + monocytes and suggests that recruitment of this proinflammatory monocyte subset to vessel walls via the CX3CR1-fractalkine pathway contributes to vascular and tissue injury.
5. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19:71-82. This is a detailed study providing evidence of two functional subsets of blood monocytes in mice and humans that have a different distribution of chemokine receptors and different affinity for inflamed tissues.
6. +) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002; 196:517-527.
7. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002; 82:521-533.
8. Dauer M, Obermaier B, Herten J, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003; 170:4069-4076.
9. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001; 194:1013-1020.
10. Chomarat P, Dantin C, Bennett L, et al. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 2003; 171:2262-2269.
11. Delneste Y, Charbonnier P, Herbault N, et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood 2003; 101:143-510. This paper presents data showing that IFN-γ controls the differentiation of antigen-presenting cells, revealing a new mechanism by which it orchestrates specific immune responses.
12. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1:510-514.
13. North RJ, Mackaness GB. Electron microscopical observations on the peritoneal macrophages of normal mice and mice immunised with Listeria monocytogenes. I. Structure of normal macrophages and the early cytoplasmic response to the presence of ingested bacteria. Br J Exp Pathol 1963; 44:601-607.
14. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35. This outstanding review covers all aspects of alternatively activated macrophages.
15. Mosser DM. The many faces of macrophage activation. J Leuk Biol 2003; 73:209-212. This is an excellent overview of classically activated, alternatively activated, and, in particular, type II activated macrophages.
16. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2:965-975.
17. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines macrophage function and renders them unresponsive to other cytokines. J Immunol 1998; 161:1983-1988.
18. Fadok VA, Henson PM. Apoptosis: giving phosphatidylserine recognition an assist - with a twist. Curr Biol 2003; 13:R655-R657. This important study demonstrates that exposed phosphatidylserine on apoptotic cells is critical for their removal.
19. Ravasi T, Wells C, Forest A, et al. Generation of diversity in the innate immune system: macrophage heterogeneity arises from gene-autonomous transcriptional probability of individual inducible genes. J Immunol 2002; 168:44-50.
20. Veillette A, Latour S, Davidson D. Negative regulation of immunoreceptor signalling. Annu Rev Immunol 2002; 20:669-707.
21. Wang MH, Zhou YQ, Chen YQ. Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activities. Scand J Immunol 2002; 56:545-553.
22. Wakayama H, Hasegawa Y, Kawabe T, et al. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcRgamma-deficient mice. Eur J Immunol 2000; 30:1182-1190.
23. Muhlfeld AS, Segerer S, Hudkins K, et al. Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membrano-proliferative glomerulonephritis. Am J Pathol 2003; 163:1127-1136. Using experimental models, this study emphasizes the important role of FcgammaRIIb in regulating immune responses.
24. Wright GJ, Puklavec MJ, Willis AC, et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000; 13:233-242.
25. Gardai SJ, Xiao YQ, Dickinson M, et al. By binding SIRPalpha or calreticulin/ CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115:13-23. This recent study of signal regulatory protein-α and one of its ligands sheds light on how inhibitory receptors that maintain the resting state might work.
26. Nikolic-Paterson DJ, Lan HY, Atkins RC. Macrophages in immune renal injury. In: Neilson EG, Couser WG, editors. Immunologic renal diseases. Philadelphia: Lippincott-Raven; 1997, pp. 575-592.
27. Rastaldi M, Ferrario F, Crippa A, et al. Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. J Am Soc Nephrol 2000; 11:2036-2043.
28. Segerer S, Mack M, Regele H, et al. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int 1999; 56:52-64.
29. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001; 37:518-531.
30. Segerer S, Hughes E, Hudkins KL, et al. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002; 62:488-495.
31. Frosch M, Vogl T, Waldherr R, et al. Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J Leukoc Biol 2004; 75:198-206; Epub 2003 Nov 03. This is an interesting example of the functional differences of glomerular macrophages in nephritis.
32. Ikezumi Y, Hurst LA, Masaki T, et al. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003; 63:83-95. An adoptive transfer approach shows the potential of macrophages to directly induce renal injury.
33. Ikezumi Y, Atkins RC, Nikolic-Paterson DJ. Interferon-gamma augments acute macrophage-mediated renal injury via a glucocorticoid-sensitive mechanism. J Am Soc Nephrol 2003; 14:888-898. Using an adoptive transfer model in which macrophage activation was manipulated in vitro by IFN-γ or dexamethasone, the authors demonstrated that it is possible to directly modulate macrophage-mediated renal injury.
34. Ozdemir BH, Demirhan B, Gungen Y. The presence and prognostic importance of glomerular macrophage infiltration in renal allografts. Nephron 2002; 90:442-446.
35. Lloyd CM, Minto AW, Dorf ME, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185:1371-1380.
36. Panzer U, Thaiss F, Zahner G, et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int 2001; 59:1762-1769.
37. Anders HJ, Frink M, Linde Y, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003; 170:5658-5666. This clear study demonstrates that despite blocking local leukocyte recruitment, chemokine antagonists can aggravate some specific disease models, probably because of interactions with systemic immune reactions.
38. Rosenkranz AR, Mendrick DL, Cotran RS, Mayadas TN. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 1999; 103:649-659.
39. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999; 56:571-580.
40. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296:155-158.
41. Nagaoka T, Kaburagi Y, Hamaguchi Y, et al. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. Am J Pathol 2000; 157:237-247.
42. Kluth DC, Rees AJ. New approaches to modify glomerular inflammation. J Nephrol 1999; 12:66-75.
43. Nishida M, Fujinaka H, Matsusaka T, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002; 110:1859-1868.
44. Erwig LP, Stewart K, Rees AJ. Macrophages from inflamed but not normal glomeruli are unresponsive to anti-inflammatory cytokines. Am J Pathol 2000; 156:295-301.
45. Wilson HM, Minto AW, Brown PA, et al. Transforming growth factor-beta isoforms and glomerular injury in nephrotoxic nephritis. Kidney Int 2000; 57:2434-2444.
46. Robertson MJ, Erwig LP, Liversidge J, et al. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci 2002; 43:2250-2257.
47. Minto AW, Erwig LP, Rees AJ. Heterogeneity of macrophage activation in anti-Thy-1.1 nephritis. Am J Pathol 2003; 163:2033-2041. This was the first study to demonstrate that macrophages infiltrating inflamed glomeruli at the same time do not respond uniformly, but are capable of engaging different activation programmes.
48. Lopez-Franco O, Suzuki Y, Sanjuan G, et al. Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol 2002; 161:1497-1505.
49. Haraguchi K, Shimura H, Onaya T. Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators. Clin Exp Nephrol 2003; 7:27-32. The authors demonstrated that peroxisome proliferator-activated receptor-γ activators exert antinephritic effects by suppressing the recruitment of inflammatory cells via a peroxisome proliferator-activated receptor-γ-dependent mechanism.
50. Kluth DC, Ainslie CV, Pearce WP, et al. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 2001; 166:4728-4736.
51. Wilson HM, Stewart K, Brown PAJ, et al. Bone marrow derived macrophages (BMDM) genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. Mol Ther 2002; 6:710-717.
52. Yokoo T, Ohashi T, Utsunomiya Y, et al. Prophylaxis of antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells. Hum Gene Ther 1999; 10:2673-2678.
53. Yamagishi H, Yokoo T, Imasawa T, et al. Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy. J Immunol 2001; 166:609-616.
54. Yokoo T, Ohashi T, Utsunomiya Y, et al. Inflamed glomeruli-specific gene activation that uses recombinant adenovirus with the Cre/loxP system. J Am Soc Nephrol 2001; 12:2330-2337.
55. Yokoo T, Ohashi T, Utsunomiya Y, et al. Gene delivery using human cord blood-derived CD34+cells into inflamed glomeruli in NOD/SCID mice. Kidney Int 2003; 64:102-109. The data indicate that umbilical cord blood cells can be utilized as a source of haematopoietic stem cells for transplantation-based therapy for glomerulonephritis.